BioSpace News Archive

Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting

Rubius Therapeutics, Inc. announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will provide a corporate update at the Jefferies London Healthcare Conference via a virtual presentation, which will be available to view on the conference website on November 18-19, 2021.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced promising preclinical safety results with berdazimer sodium in a 14-day GLP repeat dose intranasal toxicity study.

Subtle Medical, a healthcare technology company using artificial intelligence to make medical imaging faster, safer, and smarter, announced today it has received a contract for image enhancement software solutions from Vizient, the largest member-driven health care performance improvement company in the country.

Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will be participating in the following investor conferences.

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), today announced the publication of abstracts with clinical data for Iovance tumor-infiltrating lymphocyte (TIL) therapy in combination with pembrolizumab in patients with advanced cancers and for Iovance TIL cell therapy in relapsed, refractory lung cancer.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), today reported financial results for the third quarter ended September 30, 2021 and provided recent corporate updates.

AXIM Biotechnologies, Inc, an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced their publication in the Journal of Clinical Virology describing the development of a rapid test to measure levels of neutralizing antibodies to SARS-CoV-2.